Related Experiment Videos
Myeloablative therapy for follicular lymphoma
1Imperial Cancer Research Fund, Department of Medical Oncology, St. Bartholomew's Hospital, West Smithfield, London, United Kingdom.
Hematology/Oncology Clinics of North America
|October 1, 1991
Summary
Myeloablative therapy using autologous bone marrow transplantation shows promise for follicular lymphoma. Early findings suggest this treatment warrants further investigation in larger patient groups.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Follicular lymphoma is an indolent non-Hodgkin lymphoma.
- Current treatment options for follicular lymphoma have limitations.
- High-dose therapy followed by stem cell rescue is an intensive treatment strategy.
Purpose of the Study:
- To investigate the efficacy and safety of myeloablative therapy with autologous bone marrow transplantation in follicular lymphoma patients.
- To assess the preliminary outcomes of this treatment approach.
Main Methods:
- The study involves patients with follicular lymphoma undergoing myeloablative therapy.
- Autologous bone marrow transplantation is used as the stem cell source.
- Data collection focuses on treatment response and patient survival.
Main Results:
- Preliminary results indicate potential efficacy in follicular lymphoma.
- The number of patients treated and follow-up duration are currently limited.
- Observed outcomes suggest the need for continued evaluation.
Conclusions:
- Myeloablative therapy with autologous bone marrow transplantation is a promising investigational approach for follicular lymphoma.
- Further research with larger cohorts and longer follow-up is necessary to confirm these preliminary findings.